Indications : התוויות

Therapeutic indications
Breast cancer

TAXOTERE (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer.

TAXOTERE (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

TAXOTERE (docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

TAXOTERE (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease.

TAXOTERE (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

Doxorubicin and cyclophosphamide followed by TAXOTERE in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node- negative, breast cancer
TAXOTERE in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer 
Non-small cell lung cancer

TAXOTERE® (docetaxel) is indicated for the treatment of patients with advanced non-small cell lung carcinoma.

Ovarian Cancer:

TAXOTERE (docetaxel) is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.

Prostate cancer

TAXOTERE (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Esophageal cancer

TAXOTERE (docetaxel) is indicated for the treatment of esophageal cancer 
Gastric cancer

TAXOTERE (docetaxel) is indicated for the treatment of advanced gastric cancer Head and neck (SCCHN)

•    TAXOTERE as monotherapy in indicated for the treatment of patients with recurrent and/or metastatic squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

•    TAXOTERE in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

4.1.2      Additional Therapeutic Activity

Ovarian Cancer:
TAXOTERE (docetaxel) in combination with carboplatin is used for treatment of patients with advanced carcinoma of the ovary who have not previously received cytotoxic therapy for this condition.
Recommended doses are carboplatin AUC 5 plus TAXOTERE® (docetaxel) 75 mg/m2.